Summit links with Taiwan firm for lead product
This article was originally published in Scrip
Executive Summary
Summithas reached an agreement with the Taiwanese firm Orient Pharma to co-develop a buccal formulation of its lead product SMT D001. An oral formulation of the product, a combination of two marketed products with dry mouth as a side-effect, is in Phase II trials for sialorrhoea (excessive drooling) in Parkinson's disease patients. However, Summit has now suspended recruitment in this programme and will switch to the buccal formulation for future trials. Orient, a subsidiary ofOrient Europharma, will fund the development of the buccal formulation and also gains exclusive development and commercialisation rights in Asia and Australasia as part of the tie-up. It will cover all future costs related to the product in its territories, with Summit retaining rights in the rest of the world, where the UK firm is seeking partners.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.